<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02150187</url>
  </required_header>
  <id_info>
    <org_study_id>ProHair01</org_study_id>
    <nct_id>NCT02150187</nct_id>
  </id_info>
  <brief_title>Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss</brief_title>
  <official_title>Evaluation of the Efficacy of Hcap Formula Nutrition Supplement for Treatment of Men With Androgenic Alopecia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Family Marketing</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Family Marketing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HCap Formula is composed of medicinal plants, vitamins and minerals. The purpose of this&#xD;
      study is to evaluate the efficacy of HCap Formula, a nutrition supplement for promoting hair&#xD;
      growth in men with tendencies for hair loss.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of a treatment phase (6 months) and a follow-up phase (6 month ).&#xD;
      Eligible subjects will be randomly assigned to receive treatment with the study medication or&#xD;
      placebo. Subjects will visit the clinic at 3, 6, and 12 months after treatment start for&#xD;
      safety and efficacy evaluations.&#xD;
&#xD;
      HCap Formula or placebo tablets will be taken orally every other day during 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Terminal Hair Count at 26 Weeks Compared to Baseline</measure>
    <time_frame>Baseline, 26 Weeks</time_frame>
    <description>The primary outcome will be change in the terminal hair count from baseline to 26 Weeks within a 3 cm diameter circle based on macro-photographs of the same area. The treatment group will be compared to the control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of Improvement from Baseline to 26 and 52 weeks Assessed for Vertex and Frontal Views Separately</measure>
    <time_frame>Baseline, 26 weeks, 52 weeks</time_frame>
    <description>Assessment of improvement using a 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3). This assessment will be performed by comparing the global photographs obtained at Baseline with those subsequently obtained at baseline, 26, and 52 weeks. This assessment will be carried out separately on the global photography of the vertex and frontal views</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>HCap Formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pill of HCap Formula every other day for 6 month during the treatment phase; Follow up phase: nothing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Same as treatment with placebo pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HCap Formula</intervention_name>
    <description>Pill should be taken every other day during the treatment phase.</description>
    <arm_group_label>HCap Formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Similar pills without active ingredients</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males between 18-40 years of age.&#xD;
&#xD;
          2. No abnormality in blood tests analysis&#xD;
&#xD;
          3. Present with mild to moderate androgenic alopecia (AGA) graded IIv, IIIv, IV or V&#xD;
             according to the Hamilton-Norwood classification&#xD;
&#xD;
          4. Willingness to use the same shampoo, refrain from change in hair style, and refrain&#xD;
             from hair dyeing during the study.&#xD;
&#xD;
          5. Willingness to refrain from any therapy affecting hair during the study&#xD;
&#xD;
          6. Willingness to have photographs of the treated area taken.&#xD;
&#xD;
          7. Willingness to follow the treatment schedule and post treatment follow-up.&#xD;
&#xD;
          8. Willingness not participate on other studies during the study course&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          1. Having a known allergy to any of the ingredients in the test products;&#xD;
&#xD;
          2. Participation in a study of another device or drug within one month prior to&#xD;
             enrollment or during the study.&#xD;
&#xD;
             Hair treatments/ scalp condition&#xD;
&#xD;
          3. Undergone hair transplant surgery, scalp reduction surgery&#xD;
&#xD;
          4. Having hair weave or tattooing of the alopecic area.&#xD;
&#xD;
          5. Other hair loss disorders, such as alopecia areata, scarring alopecia.&#xD;
&#xD;
          6. Suffering from any active dermatological condition in the treated area such as scalp&#xD;
             atrophy, which in the opinion of the investigator might interfere with clinical&#xD;
             evaluation.&#xD;
&#xD;
             Medications&#xD;
&#xD;
             Use of the following medications within the past 6 months:&#xD;
&#xD;
          7. Prescription or over-the-counter systemic or topical treatment specific for androgenic&#xD;
             alopecia (such as minoxidil, finasteride, dutasteride).&#xD;
&#xD;
          8. 5Î±-reductase inhibitors for prostate conditions (e.g. benign prostate hyperplasia,&#xD;
             prostate cancer) and hormone replacement therapy for transgenders&#xD;
&#xD;
          9. Medications with anti-androgenic properties (cyproterone, spironolactone,&#xD;
             ketoconazole, flutamide, progesterone, and bicalutamide)&#xD;
&#xD;
         10. Medications that can potentially cause hypertrichosis (e.g. cyclosporine, diazoxide,&#xD;
             phenothiazines, zidovudine, tamoxifen, carpronium chloride),&#xD;
&#xD;
         11. Medications that can potentially cause alopecia such as oral glucocorticoids, lithium,&#xD;
             phenothiazines, tamoxifen.&#xD;
&#xD;
             Use of the following medications within the past 3 months:&#xD;
&#xD;
         12. Botanicals/nutraceuticals for hair growth&#xD;
&#xD;
         13. Steroids - systemic steroids for more than 14 days (e.g. corticosteroids, anabolic&#xD;
             steroids) or topical steroids on the area of hair loss.&#xD;
&#xD;
             Other medical conditions&#xD;
&#xD;
         14. Suffering from significant concurrent illness, such as cardiac disorders, diabetes&#xD;
             (type I or II), uncontrolled hypertension, symptomatic hypotension, hyper/hypo&#xD;
             thyroidism, or pertinent neurological disorders.&#xD;
&#xD;
         15. Suffering from serious medical condition that could adversely affect hair loss such as&#xD;
             immunosuppression/immune deficiency disorders (including HIV), history of cancer or&#xD;
             having/undergoing any form of treatment for active cancer, connective tissue disorder,&#xD;
             inflammatory bowel disease&#xD;
&#xD;
         16. As per the Investigator's discretion, any physical or mental condition which might&#xD;
             make it unsafe for the subject to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedman Skin &amp; Laser Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lilach Gavish, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Friedman Skin &amp; Laser Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr David Friedman Laser &amp; Skin Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9644035</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Androgenetic Alopecia</keyword>
  <keyword>Male</keyword>
  <keyword>Baldness</keyword>
  <keyword>hair loss pattern</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

